Literature DB >> 16762792

Diuretic use, progressive heart failure, and death in patients in the DIG study.

Michael Domanski1, Xin Tian, Mark Haigney, Bertram Pitt.   

Abstract

BACKGROUND: Nonpotassium-sparing diuretics (NPSDs), have been associated with increased sudden cardiac death (SCD) and progressive heart failure (HF) death in HF patients. METHODS AND
RESULTS: In 6797 Digitalis Investigation Group study patients, risk ratios were calculated for death, cardiovascular death (CVD), death from worsening HF, SCD, and HF hospitalization among those taking a potassium-sparing (PSD), NPSD, or no diuretic. Compared with not taking diuretic, risk of death (relative risk [RR] 1.36, 95% confidence interval [CI] 1.17-1.59, P < .0001), CVD (RR = 1.38, 95% CI 1.17-1.63, P = .0001), progressive HF death (RR = 1.41, 95% CI 1.06-1.89, P = .02), SCD (RR = 1.67, 95% CI 1.23-2.27, P = .001), and HF hospitalization (RR = 1.68, 95% CI 1.41-1.99, P < .0001) were increased with NPSD. There was no significant difference in any end point for patients taking only PSD compared to no diuretic. PSD only subjects were less likely than NPSD subjects to be hospitalized for HF (RR = 0.71, 95% CI 0.52-0.96, P = .02).
CONCLUSION: NPSDs are associated with increased risk of death, CVD, progressive HF death, SCD, and HF hospitalization. A randomized trial is needed to assess the role of NPSDs versus PSDs in HF patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762792     DOI: 10.1016/j.cardfail.2006.03.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  16 in total

1.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure.

Authors:  Jeffrey M Testani; Thomas P Cappola; Colleen M Brensinger; Richard P Shannon; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

Review 2.  Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis.

Authors:  Maria Rosa Costanzo; Mariell Jessup
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

3.  Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure.

Authors:  Jeffrey M Testani; Brian D McCauley; Jennifer Chen; Steven G Coca; Thomas P Cappola; Stephen E Kimmel
Journal:  J Card Fail       Date:  2011-10-01       Impact factor: 5.712

Review 4.  Management strategies for stage-D patients with acute heart failure.

Authors:  David Feldman; Doron M Menachemi; William T Abraham; Randell K Wexler
Journal:  Clin Cardiol       Date:  2008-07       Impact factor: 2.882

5.  The role of ultrafiltration in patients with decompensated heart failure.

Authors:  Sandeep A Kamath
Journal:  Int J Nephrol       Date:  2010-10-19

6.  Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis.

Authors:  Gregor Lindner; Edith Doberer; Andreas Vychytil; Gürkan Sengölge; Samo Wakounig; Deddo Moertl; Walter H Hörl; Wilfred Druml
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 7.  The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms.

Authors:  Christopher S Lee; Nancy C Tkacs; Barbara Riegel
Journal:  J Cardiovasc Nurs       Date:  2009 May-Jun       Impact factor: 2.083

Review 8.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

9.  Hemodynamics, diuretics, and nesiritide: a retrospective VMAC analysis.

Authors:  James B Young; Mei Cheng; Roger M Mills
Journal:  Clin Cardiol       Date:  2009-09       Impact factor: 2.882

Review 10.  Therapeutic potential of vasopressin receptor antagonists.

Authors:  Farhan Ali; Maya Guglin; Peter Vaitkevicius; Jalal K Ghali
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.